Navigate FDA Submission
05/05/2026 13:33
May 5 (Reuters) - Valion Bio Inc VBIO.O: VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION VALION BIO INC - NIAID TO FULLY FUND UP TO $7 MILLION IN VIVO STUDIES FOR ENTOLIMOD BLA Source text: ID:nPn2v93j8a Further company coverage: VBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Valion Bio
See all newsBrief: Valion Bio Reports First Quarter 2026 Financial Results
Navigate FDA Submission
Brief: Tivic Health Systems Inc To Rebrand As Valion Bio, Ticker To Vbio Effective April 28, 2026
Brief: Tivic Health Systems Inc - Appoints Michael K. Handley As CEO And Board Member Effective March 3, 2026 - SEC Filing
Brief: Tivic Health Systems Enters Stock Purchase Agreement With Tumim Stone Capital